FDA Approves Niraparib and Abiraterone Acetate Plus Prednisone for BRCA2-mutated Metastatic Castration-Sensitive Prostate Cancer By Ogkologos - January 7, 2026 43 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the AMPLITUDE study Source RELATED ARTICLESMORE FROM AUTHOR Sacituzumab Govitecan Plus Pembrolizumab Prolongs PFS Among Patients with Previously Untreated, PD-L1-positive, Advanced TNBC FDA Grants Regular Approval to Rucaparib for Metastatic Castration-Resistant Prostate Cancer FDA Approves Lisocabtagene Maraleucel for Relapsed or Refractory Marginal Zone Lymphoma MOST POPULAR FDA Grants Accelerated Approval to Zanidatamab-hrii for Patients with Previously Treated... December 17, 2024 FDA Grants Accelerated Approval to Sotorasib for KRAS G12C-mutated NSCLC June 4, 2021 Sodium Thiosulfate Prevents Cisplatin-Induced Hearing Loss in Some Children July 13, 2018 Inavolisib Plus Palbociclib–Fulvestrant Prolongs PFS in Patients with PIK3CA-mutated, HR-positive, HER2-negative... November 28, 2024 Load more HOT NEWS EMA Recommends Granting a Conditional Marketing Authorisation for Amivantamab The American Society of Clinical Oncology and the American Cancer Society:... Health-Conscious Coffee Drinkers Are Ditching the Cream and Sugar in Favor... Conducting Phase I Clinical Trials During the COVID-19 Pandemic
